Loading TrenasCycles…
Ancillary / prescription medicine
Zetia
Ezetimibe lowers LDL, the bad cholesterol that can worsen on cycle. It is not a statin and can be used alone or alongside a statin. Muscle symptoms and liver-test changes can occur, especially with other cholesterol medicines.
Labeled cholesterol treatment, with or without food. Lipid response and the full medication list guide treatment; this is not proof that an adverse steroid-related lipid profile is safe.
A meta-analysis of short controlled trials found about an 18.6% LDL reduction with monotherapy; effect on HDL is small and outcomes depend on context.
Liver-enzyme elevation (especially with statins), muscle symptoms, hypersensitivity and drug interactions.
Health problem link: elevated LDL/non-HDL cholesterol. Use a complete lipid panel and clinician-guided cardiovascular-risk assessment.
Approved to lower LDL cholesterol in appropriate patients; it does not directly correct every AAS-related lipid or cardiovascular risk.
Describes ezetimibe as a non-statin cholesterol-absorption inhibitor and supports LDL-C lowering in labeled uses.
Does not establish that ezetimibe is suitable for every patient or that LDL lowering neutralizes all cardiovascular risk.
Original source ↗Mean LDL reduction was about 18.6% in short trials.
Short duration; clinical outcomes not the main endpoint.
Original source ↗